Vestnik otorinolaringologii · 2026
[Improvement of objective diagnostic methods for acute rhinosinusitis].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ovchinnikov A Yu, Edzhe M A, Sokaeva T Yu
Аннотация
OBJECTIVE: To evaluate the diagnostic significance of nasal fractional exhaled nitric oxide (nFeNO) in patients with acute rhinosinusitis (ARS) and determine its relationship with clinical and instrumental parameters.
MATERIAL AND METHODS: The study included 44 patients with moderate acute rhinosinusitis and 33 healthy volunteers. The nFeNO level was measured using a portable electrochemical gas analyzer (NOBreath). Endoscopic assessment was performed using the modified Lund-Kennedy scale (m-LK), radiological assessment using the Lund-Mackay scale (LM), and symptom severity assessment using the SNOT-22 questionnaire. Measurements were performed at baseline, on days 7-10, and on days 30-35 of treatment.
RESULTS: Baseline nFeNO levels in ARS patients were significantly lower than in the control group (p<0.05). In unilateral lesions, decreased nFeNO levels were observed both on the affected and contralateral sides. During treatment, nFeNO levels increased and reached values comparable to the control group by days 30-35 (p>0.05). A stable negative correlation of moderate to high strength was found between nFeNO levels and the severity of clinical and radiological changes assessed by the m-LK and LM scales. The correlation with SNOT-22 scores was weak.
CONCLUSION: NFeNO is a non-invasive biomarker of inflammation in ARS reflecting the severity of the pathological process and may be used for objective assessment of disease progression and treatment efficacy.
MATERIAL AND METHODS: The study included 44 patients with moderate acute rhinosinusitis and 33 healthy volunteers. The nFeNO level was measured using a portable electrochemical gas analyzer (NOBreath). Endoscopic assessment was performed using the modified Lund-Kennedy scale (m-LK), radiological assessment using the Lund-Mackay scale (LM), and symptom severity assessment using the SNOT-22 questionnaire. Measurements were performed at baseline, on days 7-10, and on days 30-35 of treatment.
RESULTS: Baseline nFeNO levels in ARS patients were significantly lower than in the control group (p<0.05). In unilateral lesions, decreased nFeNO levels were observed both on the affected and contralateral sides. During treatment, nFeNO levels increased and reached values comparable to the control group by days 30-35 (p>0.05). A stable negative correlation of moderate to high strength was found between nFeNO levels and the severity of clinical and radiological changes assessed by the m-LK and LM scales. The correlation with SNOT-22 scores was weak.
CONCLUSION: NFeNO is a non-invasive biomarker of inflammation in ARS reflecting the severity of the pathological process and may be used for objective assessment of disease progression and treatment efficacy.